{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.18","value":"2.76"},{"groupId":"OG001","spread":"19.91","value":"5.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.68","value":"3.96"},{"groupId":"OG001","spread":"22.14","value":"6.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"title":"Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.33","value":"5.41"},{"groupId":"OG001","spread":"24.08","value":"9.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Cycle 4 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.81","value":"4.31"},{"groupId":"OG001","spread":"22.38","value":"8.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Cycle 5 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.71","value":"4.57"},{"groupId":"OG001","spread":"23.75","value":"8.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"title":"Cycle 6 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.58","value":"5.28"},{"groupId":"OG001","spread":"24.03","value":"9.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"title":"Cycle 7 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.41","value":"6.02"},{"groupId":"OG001","spread":"23.44","value":"8.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"Cycle 8 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.22","value":"4.48"},{"groupId":"OG001","spread":"24.01","value":"10.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Cycle 9 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.67","value":"4.41"},{"groupId":"OG001","spread":"23.16","value":"8.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"title":"Cycle 10 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.39","value":"4.87"},{"groupId":"OG001","spread":"25.33","value":"7.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Cycle 11 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.29","value":"5.30"},{"groupId":"OG001","spread":"25.43","value":"6.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"title":"Cycle 12 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.98","value":"5.07"},{"groupId":"OG001","spread":"25.03","value":"6.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Cycle 13 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.48","value":"4.71"},{"groupId":"OG001","spread":"24.72","value":"5.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Cycle 14 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.99","value":"3.59"},{"groupId":"OG001","spread":"26.76","value":"4.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Cycle 15 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.54","value":"7.06"},{"groupId":"OG001","spread":"26.32","value":"7.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"Cycle 16 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.23","value":"3.94"},{"groupId":"OG001","spread":"23.43","value":"3.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"Cycle 17 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.59","value":"5.80"},{"groupId":"OG001","spread":"25.32","value":"4.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Cycle 18 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.56","value":"3.94"},{"groupId":"OG001","spread":"26.40","value":"0.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Cycle 19 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.94","value":"6.50"},{"groupId":"OG001","spread":"27.78","value":"-0.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Cycle 20 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.38","value":"6.54"},{"groupId":"OG001","spread":"25.89","value":"4.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 21 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.19","value":"7.73"},{"groupId":"OG001","spread":"25.30","value":"1.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Cycle 22 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.10","value":"4.94"},{"groupId":"OG001","spread":"23.80","value":"0.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Cycle 23 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.25","value":"9.65"},{"groupId":"OG001","spread":"26.34","value":"6.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Cycle 24 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.99","value":"7.89"},{"groupId":"OG001","spread":"28.68","value":"1.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Cycle 25 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.68","value":"8.33"},{"groupId":"OG001","spread":"29.96","value":"-3.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 26 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.33","value":"8.33"},{"groupId":"OG001","spread":"28.50","value":"11.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 27 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.32","value":"14.07"},{"groupId":"OG001","spread":"23.57","value":"3.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 28 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.09","value":"7.94"},{"groupId":"OG001","spread":"21.24","value":"-1.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 29 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.21","value":"12.04"},{"groupId":"OG001","spread":"15.53","value":"6.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 30 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.56","value":"-3.41"},{"groupId":"OG001","spread":"24.90","value":"-1.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"description":"The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for future perspectives and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with data collected at specified timepoints are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)","title":"Change From Baseline in EORTC QLQ-MY20: Future Perspective","type":"SECONDARY","unitOfMeasure":"score on a scale"}